Semaglutide and Heart Issues: What the Research and Your Prescriber Need You to Know

You have a heart condition and someone's mentioned semaglutide — here's what that means in practice

Start with what the SELECT trial actually showed. Around 17,600 adults with a BMI of 27 or above and a prior history of cardiovascular disease (but no diabetes) were followed for a median of just over two and a half years. Those taking semaglutide 2.4 mg had roughly a 20% lower rate of major adverse cardiovascular events (the composite of non-fatal heart attack, non-fatal stroke, and cardiovascular death) compared with placebo. That's a meaningful result, and it was the basis for a separate UK licence for semaglutide to reduce cardiovascular event risk in eligible adults, distinct from its weight-management licence. The cardiovascular detail behind Wegovy's heart licence goes deeper into what SELECT found and who it enrolled.

The mechanism isn't fully understood. Some of the benefit likely comes from weight loss itself, less strain on the heart, improved blood pressure, better lipid profiles. But researchers suspect GLP-1 receptor activation may also have direct effects on heart tissue, separate from the scales. The two probably work together.

One thing worth doing right now: check whether you know your current resting heart rate. Thirty seconds with a finger on your wrist, or a glance at a smartwatch. It takes under a minute and gives you a useful baseline before any medicine change. You'll see why in the next section.

The heart-rate question people don't always ask first

Semaglutide, like other GLP-1 medicines, can nudge resting heart rate upward, typically by a small number of beats per minute, often in the range of one to five. For most people that's clinically unremarkable. If your baseline heart rate is already elevated, or if you have an arrhythmia or pacemaker, the picture deserves more careful attention from your prescriber. This isn't a reason to rule semaglutide out automatically; it is a reason to be transparent on your consultation form. Our dedicated page on semaglutide and heart rate changes covers what's been observed in trial data, which conditions warrant extra care, and what monitoring looks like in practice.

The modest heart-rate rise tends to be most noticeable in the early weeks and generally settles. That said, if you notice palpitations, a racing heart, or irregular beats after starting treatment, don't wait for your next scheduled review. Get in touch with your prescriber or GP. Report any suspected side effects via the MHRA's Yellow Card scheme, it contributes to the ongoing safety data that shapes future guidance.

People sometimes ask whether the cardiovascular benefit from SELECT outweighs this heart-rate nudge. For the population studied, the answer from the trial data was yes. But individual risk profiles vary, and that's precisely why semaglutide sits firmly in prescription-only territory.

What the evidence doesn't cover, and where a prescriber fills the gap

SELECT enrolled adults with established cardiovascular disease and obesity who did not have type 2 diabetes. If your situation is different (you have heart failure with reduced ejection fraction, you're managing an inherited arrhythmia, you're on anticoagulants, or you've had a recent acute cardiac event) the trial data tells you less than it might seem. The published trial results and the NHS patient information for semaglutide describe the known effects and monitoring requirements in accessible terms, but they can't account for your specific cardiac history.

There's also the broader effects of treatment to weigh. Semaglutide can cause nausea and vomiting, particularly in the first weeks at a new dose. Significant fluid losses from GI side effects matter more if you're on diuretics or medicines that affect kidney function, both common in people managing heart failure. Your prescriber needs to know your full medication list, and if you have questions about how semaglutide interacts with organ health more generally, the dedicated page on whether semaglutide causes liver issues covers what the evidence currently shows. It's also worth reading the overview of semaglutide's effects on heart health more broadly if you're looking at the longer picture beyond cardiovascular event risk.

People who are pregnant, breastfeeding, or actively trying to conceive are not suitable candidates for semaglutide; if this applies to your situation, the guidance on Wegovy and pregnancy explains the current position in detail. Those under 18 are also outside the licence for weight management, and if you're wondering whether there are any exceptions for younger patients, the page on whether teens can take Wegovy sets out the current position clearly. Every case is assessed individually by a real prescriber who reads your answers the same day, not a set of automated flags.

Getting started with semaglutide when your cardiac history is part of the picture

None of this should be read as discouragement. For many people with obesity and heart disease, semaglutide represents a genuinely evidence-backed option, not just for weight but for cardiovascular outcomes. The clinical case for it in the right patient is strong. The relevant NICE guidance for semaglutide in weight management is TA875, which sets out the licensed population and what appropriate supervision looks like.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician who reads your health history in full. If your cardiac background means a straightforward approval isn't the right call, you'll hear that clearly, along with what your options are. There are no automated gates that either wave everyone through or block reflexively on a checkbox.

If you want to understand how Wegovy fits into a broader treatment plan before committing to a consultation, the weight-loss treatment overview lays out the options without the clinical jargon. When you're ready to take the next step, you can start your free consultation and have your answers in front of a prescriber the same day.